NCT00605410已完成4 期
Duration of Protective Effect From Inhaled Ipratropium Bromide on Methacholine Airway Hyperresponsiveness
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- methacholine PC20
研究概览
简要总结
Certain lung disease medications can influence diagnostic tests and research investigations. This study will investigate how long ipratropium bromide must be withheld before a methacholine challenge test can be conducted. This information will be useful for validating current guidelines.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Diagnostic
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of asthma; stable and controlled
- •FEV1 greater than or equal to 65% predicted
排除标准
- •Concomitant lung disease other than asthma
研究组 & 干预措施
1
Active Comparator
干预措施: ipratropium bromide (Drug)
2
Placebo Comparator
干预措施: placebo (Drug)
结局指标
主要结局
methacholine PC20
时间窗: 6hours and 12 hours post inhalation
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Clinical and Medico-economic Validation of the HEPHAI Solution.Asthma COPDNCT06099145Hephai238
进行中（未招募）
3 期
Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination in pMDI Form in Stable Chronic Obstructive Pulmonary Disease (COPD) PatientsCOPDNCT06040424Neutec Ar-Ge San ve Tic A.Ş74
已完成
4 期
Duration of Long Acting Muscarinic Antagonist (LAMA) Bronchoprotection Against Methacholine ChallengeAsthmaNCT02622243University of Saskatchewan13
已完成
3 期
Efficacy and Safety of Tiotropium Compared to Salmeterol and Placebo in Patients With Chronic Obstructive Bronchitis (COPD)Pulmonary Disease, Chronic ObstructiveNCT02173691Boehringer Ingelheim584
已完成
不适用
A Survey for Long-term Use of Prograf Capsules in Patient With Interstitial PneumoniaInterstitial Pneumonia Associated With Polymyositis/DermatomyositisNCT02159651Astellas Pharma Inc179